Cargando…

Bayes factors for superiority, non-inferiority, and equivalence designs

BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null...

Descripción completa

Detalles Bibliográficos
Autores principales: van Ravenzwaaij, Don, Monden, Rei, Tendeiro, Jorge N., Ioannidis, John P. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441196/
https://www.ncbi.nlm.nih.gov/pubmed/30925900
http://dx.doi.org/10.1186/s12874-019-0699-7
_version_ 1783407513775898624
author van Ravenzwaaij, Don
Monden, Rei
Tendeiro, Jorge N.
Ioannidis, John P. A.
author_facet van Ravenzwaaij, Don
Monden, Rei
Tendeiro, Jorge N.
Ioannidis, John P. A.
author_sort van Ravenzwaaij, Don
collection PubMed
description BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), after which the probabilities of obtaining data more extreme than those observed under these null hypotheses are quantified by p-values. Although ubiquitous in clinical testing, the null hypothesis significance test can lead to a number of difficulties in interpretation of the results of the statistical evidence. METHODS: We advocate quantifying evidence instead by means of Bayes factors and highlight how these can be calculated for different types of research design. RESULTS: We illustrate Bayes factors in practice with reanalyses of data from existing published studies. CONCLUSIONS: Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They also allow for interim testing without the need to employ explicit corrections for multiple testing.
format Online
Article
Text
id pubmed-6441196
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64411962019-04-11 Bayes factors for superiority, non-inferiority, and equivalence designs van Ravenzwaaij, Don Monden, Rei Tendeiro, Jorge N. Ioannidis, John P. A. BMC Med Res Methodol Technical Advance BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), after which the probabilities of obtaining data more extreme than those observed under these null hypotheses are quantified by p-values. Although ubiquitous in clinical testing, the null hypothesis significance test can lead to a number of difficulties in interpretation of the results of the statistical evidence. METHODS: We advocate quantifying evidence instead by means of Bayes factors and highlight how these can be calculated for different types of research design. RESULTS: We illustrate Bayes factors in practice with reanalyses of data from existing published studies. CONCLUSIONS: Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They also allow for interim testing without the need to employ explicit corrections for multiple testing. BioMed Central 2019-03-29 /pmc/articles/PMC6441196/ /pubmed/30925900 http://dx.doi.org/10.1186/s12874-019-0699-7 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Technical Advance
van Ravenzwaaij, Don
Monden, Rei
Tendeiro, Jorge N.
Ioannidis, John P. A.
Bayes factors for superiority, non-inferiority, and equivalence designs
title Bayes factors for superiority, non-inferiority, and equivalence designs
title_full Bayes factors for superiority, non-inferiority, and equivalence designs
title_fullStr Bayes factors for superiority, non-inferiority, and equivalence designs
title_full_unstemmed Bayes factors for superiority, non-inferiority, and equivalence designs
title_short Bayes factors for superiority, non-inferiority, and equivalence designs
title_sort bayes factors for superiority, non-inferiority, and equivalence designs
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441196/
https://www.ncbi.nlm.nih.gov/pubmed/30925900
http://dx.doi.org/10.1186/s12874-019-0699-7
work_keys_str_mv AT vanravenzwaaijdon bayesfactorsforsuperioritynoninferiorityandequivalencedesigns
AT mondenrei bayesfactorsforsuperioritynoninferiorityandequivalencedesigns
AT tendeirojorgen bayesfactorsforsuperioritynoninferiorityandequivalencedesigns
AT ioannidisjohnpa bayesfactorsforsuperioritynoninferiorityandequivalencedesigns